$阿斯利康(AZN.US)$Ultomiris now approved for Tx of neuromyelitis optica spectrum disorder (NMOSD) ⇒ sBLA approved as 4th indication 👏 ⇒ 1st and only long-acting C5 complement inhibitor, offers Px with AQP4 Ab+ ⇒ CHAMPION-NMOSD trial - met primary endpoint 🔬 ⇒ Ultomiris (ravulizumab-cwvz) inj., for IV use 💉
Despite AstraZeneca's strong performance, its stock is down. The author recommends buying AZN stock under $66, citing key products, strong pipelines, and recent acquisitions as growth drivers.
RECAP Stocks closed higher Tuesday, ramping up from a morning pullback as the market reacted to the news that$英伟达(NVDA.US)$announced a large computer chip for AI processing at its GTC event Monday night. Investors await the FOMC policy statement on Wednesday, where the market has priced in a 99% chance of no rate change. With preliminary numbers, the$标普500指数(.SPX.US)$climbed 0.56% to its 18th record close of the year at ...
The development and marketing of ADCs are likely to significantly benefit the bottom lines of pharmaceutical and biotech companies involved in their production. Companies like ImmunoGen and ADC Therapeutics are also highlighted as ones to watch in the ADC space.
阿斯利康股票讨论区
"Rare" 💉💔
🎯 Ph 3 readouts in Q2 2024...
$CG Oncology(CGON.US)$ Phase 3
$美国联合医疗(UTHR.US)$ Phase 3
$美国联合医疗(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$乌龙制药(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...
FDA PDUFA Update…
$Supernus Pharmaceuticals(SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$传奇生物(LEGN.US)$ & $强生(JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$阿斯利康(AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US)$ & $施贵宝(BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$万达生物制药(VNDA.US)$...
FDA PDUFA Update…
$Akebia Therapeutics(AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$默沙东(MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$阿斯利康(AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$再生元制药公司(REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$阿斯利康(AZN.US)$ : 🤔
⇒...
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$默沙东(MRK.US)$ x $Immunovant(IMVT.US)$
$礼来(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元制药公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科学(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施贵宝(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$礼来(LLY.US)$ x $Merus(MRUS.US)$ (partner n...
Biotech Stock Catalyst Watchlist
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$和黄医药(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$乌龙制药(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...
neuromyelitis optica spectrum disorder (NMOSD)
⇒ sBLA approved as 4th indication 👏
⇒ 1st and only long-acting C5 complement inhibitor,
offers Px with AQP4 Ab+
⇒ CHAMPION-NMOSD trial - met primary endpoint 🔬
⇒ Ultomiris (ravulizumab-cwvz) inj., for IV use 💉
专栏Wall Street Today | Market Reverses, Decides Big Chips Are Good
Stocks closed higher Tuesday, ramping up from a morning pullback as the market reacted to the news that $英伟达(NVDA.US)$ announced a large computer chip for AI processing at its GTC event Monday night. Investors await the FOMC policy statement on Wednesday, where the market has priced in a 99% chance of no rate change.
With preliminary numbers, the $标普500指数(.SPX.US)$ climbed 0.56% to its 18th record close of the year at ...
暂无评论